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The BARD1-CstF-50 Interaction Links mRNA 39 End
Formation to DNA Damage and Tumor Suppression
Scully et al., 1997b; Bhattacharyya et al., 2000). Consis-
tent with this, mouse embryonic stem cells deficient
in BRCA1 are defective in transcription-coupled repair
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(TCR) of oxidative DNA damage (Gowen et al., 1998)New York, New York 10027
and in double-strand break repair by homologous re-
combination (Moynahan et al., 1999). BRCA1 also has
been suggested to function in transcription by its inter-Summary
action with several components of the transcriptional
complex, including the RNA polymerase II (RNAP II) ho-The mRNA polyadenylation factor CstF interacts with
loenzyme (Scully et al., 1997a), RNA helicase A (Ander-the BRCA1-associated protein BARD1, and this inter-
son et al., 1998), and CtIP, a protein implicated in theaction represses the nuclear mRNA polyadenylation
CtBP pathway of transcriptional repression (Yu et al.,machinery in vitro. Given the suspected role of BRCA1/
1998). Moreover, the BRCT domain of BRCA1 can acti-BARD1 in DNA repair, we tested whether inhibition of
vate transcription (Chapman and Verma, 1996), andmRNA processing is linked to DNA damage. Strikingly,
BRCA1 association with p53 can stimulate p539s tran-we found that 39 cleavage in extracts from cells treated
scriptional activity (Ouchi et al., 1998). Although less iswith hydroxyurea or ultraviolet light was strongly, but
known about the function of BARD1, our recent studiestransiently, inhibited. Although no changes were de-
showed that BARD1 interacts with the polyadenylationtected in CstF, BARD1, and BRCA1 protein levels, in-
factor CstF and inhibits 39 end processing of mRNAcreased amounts of a CstF/BARD1/BRCA1 complex
precursors (Kleiman and Manley, 1999).were detected. Supporting the physiological signifi-
The above results are consistent with the idea thatcance of these results, a previously identified tumor-
BRCA1, likely in association with BARD1, functions bothassociated germline mutation in BARD1 (Gln564His)
in transcription and in DNA repair. Links between tran-reduced binding to CstF and abrogated inhibition of
scription and DNA repair are well established (reviewedpolyadenylation. Together these results indicate a link
by de Laat et al., 1999). BRCA1 could play a direct rolebetween mRNA 39 processing and DNA repair and tu-
in DNA repair, or it could play a bifunctional role as amor suppression.
factor involved in processing DNA lesions (Scully et al.,
1997b; Bhattacharyya et al., 2000; Welcsh et al., 2000)Introduction
and/or as a transcriptional activator of certain genes
involved in the response to DNA damage (Ouchi et al.,Germline alterations of the BRCA1 gene result in sus-
1998; Welcsh et al., 2000).ceptibility to breast and ovarian cancer (reviewed in
Links between transcription and mRNA processingWelcsh et al., 2000). BRCA1-associated RING domain
have also been described. Factors involved in the majorprotein (BARD1) interacts with BRCA1; both proteins
steps of mRNA processing are recruited by the C-termi-possess NH2-terminal RING motifs and COOH-terminal
nal domain of the RNAP II largest subunit (CTD) andBRCT domains, with the former responsible for the
delivered to the nascent mRNA at their sites of actionBARD1/BRCA1 interaction (Wu et al., 1996; Ayi et al.,
(reviewed by Hirose and Manley, 2000). Specifically, 391998; Meza et al., 1999). Inhibition of BARD1 expression
end processing is coupled to transcription by the CTDin cultured cells results in changes suggestive of a pre-
(McCracken et al., 1997); both cleavage stimulation fac-malignant phenotype (Irminger-Finger et al., 1998), and
tor (CstF) and cleavage-polyadenylation specificity fac-
the existence of BRCA1 tumorigenic mutations that im-
tor (CPSF) interact with the CTD (McCracken et al.,
pair formation of the BARD1/BRCA1 complex (Wu et al.,
1997). CPSF can associate with RNAP II at the promoter
1996) and of tumorigenic mutations in BARD1 (Thai et via an interaction with the transcription factor TFIID
al., 1998) also supports the view that BARD1 is involved (Dantonel et al., 1997), and appears to remain with it
in BRCA1-mediated tumor suppression. A germline mu- during elongation (McCracken et al., 1997). The CTD is
tation in BARD1 (Gln564His) was identified in ovarian, in fact required for efficient endonucleolytic cleavage of
breast, and uterine tumors of one patient (Thai et al., the pre-mRNA in vitro (Hirose and Manley, 1998).
1998). The formation of a polyadenylated [poly(A)] tail at the
In contrast to the studies linking BRCA1 and BARD1 39 end of mRNA precursors involves endonucleolytic
to tumor suppression, the normal cellular functions of cleavage coupled with poly(A) synthesis, a reaction that
these proteins have proven more difficult to define. Sev- requires a complex set of proteins factors (reviewed by
eral lines of evidence support a role for BRCA1 in main- Colgan and Manley, 1997; Zhao et al., 1999). One of
taining genomic stability in response to DNA damage these factors, CstF, is required for the endonucleolytic
(reviewed in Welcsh et al., 2000). BRCA1, in association cleavage step and helps to specify the site of pro-
with BARD1, can colocalize with the DNA replication and cessing. CstF is a heterotrimeric protein with subunits
repair factors PCNA and Rad51, perhaps participating in of 77, 64, and 50 kDa. CstF-64 and CstF-77 (Suppressor-
the cellular response to DNA damage (Jin et al., 1997; of-forked in Drosophila) are largely responsible for RNA
binding (MacDonald et al., 1994; Takagaki and Manley,
1997) and for interactions with other polyadenylation* To whom correspondence should be addressed (e-mail: jlm2@
columbia.edu). factors (Takagaki and Manley, 1994; Murthy and Manley,
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Figure 1. Inhibition of 39 End Processing in Response to DNA Damage
(A) Effect of HU treatment on SV40 late pre-mRNA 39 cleavage. Cleavage reactions were carried out in presence of 2 mM EDTA. Positions of
pre-mRNA and the 59 and 39 cleavage products are indicated.
(B) Effect of UV irradiation on SVL pre-mRNA 39 cleavage. NEs from treated cells were used for 39 cleavage reactions performed and analyzed
as in (A).
(C) Effect of UV irradiation on L3 pre-mRNA 39 cleavage. NEs were the same ones used in the cleavage reactions described in panel (B).
Reactions were performed and analyzed as in (A) in the presence of 1 mM MgCl2 and 1 mM 39 dATP.
(D) The inhibitory effect of DNA damage is not due to a diffusible inhibitor. Similar amounts of total NE protein prepared from cells 0 or 5 hr
after UV irradiation were used in 39 cleavage reactions either alone or mixed. Reactions were performed and analyzed as in (A).
(E) Inhibition by DNA damage is specific to 39 end processing. Splicing of b-globin pre-mRNA was analyzed in NE from cells treated with HU
or UV. NEs were the same ones used in the reactions described in panels (A) and (B). Positions of the pre-mRNA, intermediates, and products
are indicated schematically.
1995), respectively. CstF-50 contains seven WD-40 re- adenylation might function to prevent inappropriate
RNA processing during transcription, perhaps at sitespeats, motifs involved in protein–protein interactions
(Takagaki and Manley, 1992) and which are characteris- of TCR. Here we report that treatment of cells with DNA
damage-inducing agents causes a transient, but spe-tic of regulatory proteins (Neer et al., 1994). CstF-50
has been shown to interact with BARD1 (Kleiman and cific, inhibition of mRNA 39 end processing in cell ex-
tracts. We provide evidence that this inhibition reflectsManley, 1999), with the CTD (McCracken et al., 1997),
and with the DNA replication/repair factor PCNA (Klei- the BARD1/CstF interaction and involves enhanced for-
mation of a CstF/BARD1/BRCA1 complex. A tumor-man and Manley, 1999). A good deal of recent evidence
suggests that regulation of polyadenylation may play a associated germline mutation in BARD1 decreases
binding to CstF-50 and renders the protein inactive insignificant role in cell growth control (Colgan et al., 1996,
1998; Takagaki et al., 1996; Takagaki and Manley, 1998; polyadenylation inhibition. These results support the ex-
istence of an unexpected link between RNA 39 end for-Zhao and Manley, 1998; Chuvpilo et al., 1999) and in
disease, especially in tumor cells (e.g., Kumar et al., mation and DNA repair/tumor suppression.
1995; Scorilas et al., 1998).
Recently, we found that CstF-50 interacts with BARD1 Results
in vitro and, together with BRCA1, in vivo, and that this
interaction represses the polyadenylation machinery in DNA Damage Inhibits Polyadenylation In Vitro
BARD1, together with BRCA1, interacts with the mRNAin vitro functional assays (Kleiman and Manley, 1999).
We suggested that BARD1-mediated inhibition of poly- polyadenylation factor CstF-50 and represses the activ-
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ity of the polyadenylation machinery in vitro (Kleiman
and Manley, 1999). Given the evidence that BRCA1,
likely in association with BARD1, plays a role in the
cellular response to DNA damage (Jin et al., 1997; Scully
et al., 1997b), we wished to test the possibility that the
observed inhibition of polyadenylation by BARD1 might
also reflect a response to DNA damage. To test this
idea, we first exposed asynchronous HeLa cells to hy-
droxyurea (HU) for different periods of time. HU is a
reversible ribonucleotide reductase inhibitor that de-
pletes deoxyribonucleotide pools, thereby inhibiting
DNA synthesis and mimicking DNA damage (e.g., Scully
et al., 1997b). Nuclear extracts (NE) were prepared from
these cells and used in in vitro 39 processing reactions.
Strikingly, 39 cleavage of an SV40 pre-mRNA substrate
was strongly, but transiently, inhibited (Figure 1A). Inhi-
bition was observed from 2–8 hr of HU treatment, but
cleavage was restored after 10 hr, reaching the levels
of untreated cells. As discussed below, the transient
nature of the inhibition is consistent with previously
characterized responses to DNA damage and, in any
event, indicates that the effect was not due to an irre-
Figure 2. Protein Levels of Polyadenylation Factors and BARD1/
versible effect of HU. BRCA1 Do Not Change Following UV Treatment
We next analyzed the effect of authentic DNA damage CstF-64, BARD1, CPSF-160, and BRCA1 protein levels in NEs from
on the 39 end cleavage reaction. Asynchronous HeLa UV-treated HeLa cells were monitored by Western blotting. Proteins
cells were treated with ultraviolet (UV) irradiation and were detected by immunoblotting with antibodies against CstF-64
(A), BARD1 (B), CPSF-160 (C), and BRCA1 (D). The positions of eachallowed to recover for the times indicated in Figure 1B.
protein are indicated in the corresponding panel. In (B), the asteriskRemarkably, NEs prepared from these cells also showed
denotes an unknown species detected by the anti-BARD1 mAb.strong inhibition of cleavage, and inhibition was again
Although certain of its properties suggest that it is related to BARD1,
transient, increasing between 2 and 8 hr after treatment its relationship to BARD1 is currently unknown (Kleiman and Manley,
and disappearing after 10 hr. Essentially identical results 1999).
were observed with another pre-mRNA substrate, ade-
novirus L3 (Figure 1C), indicating that the inhibition was
(CstF-64 and CPSF-160) in response to UV (Figures 2A
likely a general effect on 39 end formation, and not re-
and 2C, respectively) or HU (data not shown), indicating
lated to the unusual PAP independence of SV40 late
that cleavage inhibition was not due to decreased con-
pre-mRNA 39 cleavage (e.g., Hirose and Manley, 1998).
centrations of these two important cleavage factors.
Cleavage was not inhibited in reaction mixtures in which Since BARD1 forms a complex with CstF and inhibits
NE from untreated and 5 hr UV-treated cells were mixed polyadenylation in vitro (Kleiman and Manley, 1999),
(Figure 1D), suggesting that the treated extracts did not changes in its expression level could explain the de-
contain excess amounts of a diffusible inhibitor. Both crease in 39 end formation observed under DNA damage
HU and UV-treated NEs were also tested for their ability conditions. However, Western blotting revealed that nei-
to perform pre-mRNA splicing. Although there was some ther BARD1 (Figure 2B) nor BRCA1 (Figure 2D) levels
variability, no significant decreases in splicing efficiency changed significantly in response to UV treatment. This
were detected at the times 39 cleavage was inhibited, result is consistent with the fact that the steady-state
indicating that extracts were not generally inactivated levels of BARD1 and BRCA1 remain relatively constant
(Figure 1E). Together, these results provide evidence during cell cycle progression (Jin et al., 1997; Scully
that DNA damage can cause a strong and specific, but et al., 1997b). However, reversible changes in the gel
transient, inhibition of pre-mRNA 39 end formation. mobility of BRCA1, presumably reflecting phosphoryla-
tion, were detected in extracts from cells treated with
UV (Figure 2D) or HU (data not shown), and the timing
DNA Damage Increases Formation of a CstF/ correlated well with cleavage inhibition. Very similar
BARD1/BRCA1 Inhibitory Complex changes in BRCA1 phosphorylation in response to DNA
In an effort to understand the mechanisms governing damage have been observed previously and shown to
the inhibition of 39 cleavage observed in response to correlate with BRCA1/BARD1 complex formation and/
DNA damage conditions, we first analyzed the levels of or relocalization to possible sites of DNA damage (Ruff-
different proteins involved in 39 end cleavage and its ner and Verma, 1997; Scully et al., 1997b).
control in the NEs from treated cells. Certain cellular As no changes were detected in CstF-64, BARD1,
events are sensitive to the expression level of these and BRCA1 protein levels in the treated cells, another
proteins, for example, cell growth and aspects of gene possibility is that cleavage inhibition was due to in-
expression in B cells are sensitive to CstF-64 levels creased formation or stability of a CstF/BARD1/BRCA1-
(Takagaki and Manley, 1998). Western blots revealed no containing inhibitory complex (Kleiman and Manley,
1999). To examine the status of the CstF/BARD1/BRCA1significant changes in components of CstF and CPSF
Cell
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Figure 3. CstF/BARD1/BRCA1 Complex Formation Increases Transiently Following DNA Damage
CstF, BARD1, and BRCA1 coimmunoprecipitate from NEs of HeLa cells treated with UV irradiation. NEs were immunoprecipitated with anti-
CstF-64 (A) or anti-BRCA1 (B) antibodies. Equivalent amounts of the pellets (IP) and supernatants (SUP) were resolved by SDS-PAGE and
proteins were detected by immunoblotting with anti-BRCA1, anti-BARD1, or anti-CstF-64. Positions of BRCA1, BARD1, and CstF-64 are
indicated. Asterisks denote the possible BARD1-related species (see Figure 2B).
complex upon exposure to DNA damaging conditions, The BARD1/CstF Interaction Is Responsible
for DNA Damage-Inducedwe analyzed the complex in NEs from UV-treated cells
by coimmunoprecipitation, using mAbs against CstF-64 Polyadenylation Inhibition
The experiments presented so far were based on the(Figure 3A) and BRCA1 (Figure 3B). Although BARD1
interacts directly with the CstF-50 subunit of CstF, this observations that BARD1 can associate with polyade-
nylation factors and inhibit cleavage in vitro, and on theinteraction involves intact CstF, as reflected by the abil-
ity of the anti-CstF-64 mAb to immunoprecipitate the suspected role of BRCA1/BARD1 in DNA repair. The
specific inhibition of polyadenylation in response to DNAcomplex (Kleiman and Manley, 1999). Similar results
were obtained with both monoclonal antibodies. The damaging agents and the concomitant increase of a
CstF/BARD1/BRCA1 complex are consistent with theresults indicate that, as observed previously, antibodies
against either protein coprecipitated a small fraction of idea that BARD1 functions in this inhibition, but do not
provide direct evidence for it. To address this, we tookthe other proteins (CstF-64, BARD1, or BRCA1) in NE
active for cleavage. Most importantly, the amount of advantage of our previous observation that 39 cleavage
could be enhanced by preincubation of limiting amountsprotein that coprecipitated increased significantly in the
NEs inhibited for cleavage. This increase was especially of NE with increasing amounts of an anti-BARD1 mAb
(Kleiman and Manley, 1999). NEs prepared from UV-striking with respect to the amount of CstF-64 that coim-
munoprecipitated with the BRCA1 mAb, greatly increas- treated cells were preincubated with either anti-BARD1
(Figure 4A) or control mAbs directed against actin (Fig-ing at 2, 5, and 8 hr post-UV time points (Figure 3B; data
for 8 hr not shown). As with cleavage inhibition, the ure 4B) or p53 (Figure 4C). Strikingly, the addition of the
anti-BARD1 mAb to the inhibited NEs increased theirenhanced complex formation was transient, returning
to near zero time levels after 10 hr. Extraneous antibod- levels of cleavage, allowing efficiencies similar to that
observed in untreated NE. The addition of the controlies did not immunoprecipitate either of these proteins,
nor did either antibody cross-react with the other pro- mAbs to the NEs was without effect, indicating that the
enhancement of cleavage was specific for the BARD1teins (data not shown). These results indicate that CstF/
BARD1/BRCA1 association is enhanced by DNA dam- mAb. In these experiments, the amount of NE was not
limiting, so the increase in cleavage in the noninhibitedage at times coincident with the observed inhibition of
39 cleavage. NE was minimal after addition of anti-BARD1 mAb (com-
pare “0 hr” in panels A and B, Figure 5). Rescue byIt has been reported that BARD1/BRCA1 association
increases during S phase (Scully et al., 1997b). To test the anti-BARD1 mAb was concentration dependent, as
shown by the response to increasing amounts of thewhether the increased BARD1/BRCA1/CstF interaction
might also be cell cycle related, we determined, by FACS mAb (Figure 4C). These results indicate that BARD1 is
necessary for the cleavage inhibition induced followinganalysis, the cell cycle distribution of UV-treated cells
at 0 time and at the times analyzed above. The results DNA damage.
If BARD1 indeed inhibits polyadenylation by interac-(not shown) revealed a modest decrease in S phase and
G2/M cells and increase in G0/G1 cells over the 10 hr tion with CstF, then addition of purified CstF should
enhance the levels of 39 processing in NEs preparedtime course. Thus, the increase in complex formation
does not reflect an increase in S phase cells, and is not from UV-treated cells. NEs prepared from 0 hr and 5 hr
post-UV cells were therefore analyzed for 39 cleavagecorrelated with changes in cell cycle.
Pre-mRNA Processing and DNA Repair
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Figure 4. BARD1 Is Necessary for the DNA Damage-Induced Inhibition of Polyadenylation
(A) Anti-BARD1 antibodies activate the 39 cleavage in NEs of UV-treated cells. The same NEs used in the 39 cleavage reactions described in
Figure 1B were preincubated with 200 ng of purified anti-BARD1 mAb in presence of 1 mM MgCl2.
(B) Anti-actin antibodies do not activate the 39 cleavage in NEs of UV-treated cells. Reactions were performed and analyzed as in (A).
(C) Activation of cleavage by anti-BARD1 antibodies is dose dependent. NEs inactive for 39 cleavage (5 hr UV treatment, Figure 1B) were
preincubated with no addition (lane 1) or with increasing amounts (100, 200, and 300 ng) of a purified anti-BARD1 (lanes 3–5) or anti-p53 (300
ng, lane 2) mAb.
(D) Activation of cleavage by the addition of CstF. NEs active (0 hr UV treatment, Figure 1B) and inactive (5 hr UV treatment, Figure 1B) for
39 cleavage were preincubated with no addition (lanes 1 and 5) or with increasing amounts (10, 20, and 30 ng) of MonoS purified CstF (lanes
2–4 and 6–8).
in the presence of increasing amounts of purified CstF function of BARD1 in tumor suppression, we took advan-
tage of an analysis of tumor-associated mutations in(Figure 4D; Takagaki et al., 1990). Addition of CstF to
the zero time NEs modestly enhanced cleavage (Figure BARD1 (Thai et al., 1998).
We were intrigued by the fact that the only known4D), indicating that CstF may be limiting for processing
under these conditions. However, addition of CstF to tumor-associated germline mutation in BARD1
(Gln564His) was found to lie within the CstF-50 interac-the inhibited NE strongly increased cleavage, allowing
efficiencies similar to that observed in the nontreated NE tion domain (Kleiman and Manley, 1999). In order to
investigate the possible effects of this mutation onat the highest CstF concentration. These results provide
strong evidence that CstF is indeed the target of BARD1- BARD1 function in polyadenylation, we constructed a
GST-BARD1 fusion protein containing the Gln564Hismediated inhibition in extracts prepared from UV-
treated cells. mutation (Figure 5A). The proteins were first used in
binding assays with in vitro translated CstF-50, as de-
scribed previously (Kleiman and Manley, 1999). As ex-A Tumor-Associated Mutation in BARD1
Abolishes BARD1-Mediated Inhibition pected, a significant amount of the input CstF-50 bound
to GST-BARD1 but not to GST alone (Figure 5C). Theof mRNA Polyadenylation
The above data provide considerable support for the Gln564His mutation significantly and reproducibly re-
duced binding, indicating that this residue is importantexistence of an inhibitory effect of DNA damage on pre-
mRNA polyadenylation, and for this response being me- for optimal interaction. This is similar to the behavior of a
GST-BARD1 derivative with a COOH-terminal truncationdiated at least in part by BARD1. To obtain genetic
support for the significance of this interaction, as well removing most of the BRCT domain (GST-BARD1 (13–
638); Figure 5A), which also displayed reduced bindingas to test the idea that it might be related to the possible
Cell
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Figure 5. A Tumor-Associated Mutation in BARD1 Specifically Decreases Interaction with CstF-50 In Vitro
(A) Diagram of GST-BARD1 derivates. Features of the proteins are indicated: the RING motif (residues 44–90), the three ankyrin repeats
(residues 427–525), and the BRCT domain (residues 605–777). Two BARD1 mutants are also diagrammed: a COOH-terminal truncated version,
which lacks most of the BRCT domain, and the Gln564His protein, which carries the tumor-associated missense mutation. Numbers represent
amino acid residues.
(B) Coomassie blue staining of the purified GST-BARD1 derivates following SDS-PAGE. Positions of size markers are indicated.
(C) Interaction of BARD1 and CstF-50. CstF-50 was produced by in vitro translation and incubated with purified GST (lane 2) or the indicated
GST-BARD1 derivative (lanes 3–5). Five percent of the CstF-50 used in binding reactions is shown in lane 1.
(D) Interaction of BARD1 and CstF-50 in different salt concentrations. Reactions were performed and analyzed as in (C), except for the washing
conditions. Washing was with buffer A and increasing concentrations of NaCl (200, 300, 400, 500, and 600 mM). Five percent of the CstF-50
used in binding reactions is shown in lane 1.
(E) Interaction of BARD1 and BRCA1. BRCA1 was produced by in vitro translation and incubated with purified GST (lane 2) or the indicated
GST-BARD1 derivative (lanes 3–5). Binding reactions were performed and analyzed as in (C).
(F) BARD1 homodimer formation. Full-length BARD1 was produced by in vitro translation and incubated with purified GST (lane 2) or the
indicated GST-BARD1 derivative (lanes 3–5). Binding reactions were performed and analyzed as in (C).
(see also Kleiman and Manley, 1999). To examine the due to general misfolding of the protein or to some other
nonspecific effect.effect of the Gln564His mutation on the BARD1/CstF-50
interaction in more detail, we determined the sensitivity We next wished to determine whether the Gln564His
mutation influences the inhibitory effect of BARD1 onof the interaction to elevated salt concentrations (Figure
5D). Increasing the NaCl concentration in the washing 39 cleavage in NE. We first analyzed the ability of the
wild-type and Gln564His mutant GST-BARD1 proteinsbuffer resulted in a significant decrease in the amount
of CstF-50 bound to GST-BARD1 Gln564His, such that to interact with intact CstF and, as a control, BRCA1
in standard HeLa NEs used for processing reactions.binding was nearly undetectable at the highest concen-
tration. Elevated salt also reduced binding to wild-type Bound proteins were detected by Western blotting using
anti-CstF-64 and BRCA1 antibodies (Figure 6A). A signif-GST-BARD1, but the decrease was relatively minor.
Thus, under more stringent conditions, the tumor-asso- icant amount of CstF-64 bound to GST-BARD1 but not
to GST alone. Importantly, the Gln564His mutation sig-ciated Gln564His mutation strongly inhibits the BARD1/
CstF-50 interaction. nificantly reduced binding, indicating that the mutation
affects interaction with intact CstF as well as with CstF-BARD1 can homodimerize as well as form heterodi-
mers with BRCA1 via its NH2-terminal domain, which 50 (see above). As expected, both GST-BARD1 deri-
vates showed similar binding to endogenous BRCA1.includes a RING finger motif (Wu et al., 1996; Ayi et al.,
1998; Meza et al., 1999). We next examined whether the We next monitored 39 cleavage of the SV40 pre-mRNA
in standard NE incubated with no addition or with in-Gln564His mutation affected either of these interactions,
using the three GST-BARD1 derivates employed above creasing amounts of each of the three GST-BARD1 deri-
vates analyzed in Figure 6B. As observed before (Klei-and in vitro translated BRCA1 and BARD1 in binding
assays (Figures 5E and 5F, respectively). A significant man and Manley, 1999), addition of increasing amounts
of purified GST-BARD1 to reaction mixtures effectivelyamount of the input BARD1 and BRCA1 bound to GST-
BARD1 but not to GST. However, both of the GST- inhibited cleavage, almost completely at the highest
concentrations (Figure 6B, lanes 8–10). Strikingly, theBARD1 mutants, and most importantly the Gln564His
derivative, displayed the same level of binding as wild GST-BARD1 Gln564His protein was without detectable
effect on cleavage at all concentrations tested (lanestype. These results indicate that the observed decrease
in binding of the Gln564His protein to CstF-50 was not 2–4). In contrast, and also as shown before (Kleiman
Pre-mRNA Processing and DNA Repair
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Figure 6. The Gln564His Mutation Abolishes the Inhibitory Effect of BARD1 on 39 Cleavage In Vitro
(A) Interaction of cellular CstF and BRCA1 with GST-BARD1 derivatives. NEs were incubated with GST (lanes 1 and 4) or the indicated GST-
BARD1 derivative (lanes 2–3 and 5–6). Equivalent amounts of the pellets (pulldown) and supernatants (SUP) were resolved by SDS-PAGE and
proteins were detected by immunoblotting with anti-BRCA1 or anti-CstF-64. Positions of BRCA1 and CstF-64 are indicated.
(B) HeLa NE was incubated with no addition (lane1) or with increasing amounts (50, 100, and 150 ng) of the indicated GST-BARD1 derivative
(lanes 2–10). The 39 processing reaction was carried out in presence of 1 mM MgCl2. Positions of pre-mRNAs and the 59 cleavage product
are indicated.
and Manley, 1999), GST-BARD1 (13–638) still inhibited replicating DNA-containing structures. It is conceivable
that these changes, which are first detectable about 30processing, although less efficiently than did GST-
min following UV treatment, contribute to formation ofBARD1, consistent with the less significant effect of
the BRCA1/BARD1/CstF inhibitory complex. It is alsothis mutation, relative to the Gln564His mutation, on
noteworthy that the yeast two-hybrid screen that re-interaction with CstF-50. These results indicate that glu-
vealed the CstF-50/BARD1 interaction also detected atamine 564 plays a critical role in the function of the
strong interaction between CstF-50 and PCNA (KleimanBARD1 cleavage inhibitory domain.
and Manley, 1999), consistent with the idea that BRCA1/
BARD1/CstF complex may target DNA repair sites
Discussion marked by PCNA.
Also related to our findings may be the ubiquitination
In this study, we have investigated the significance of of a fraction of the largest subunit of RNAP II that occurs
the previously described inhibitory interaction between following DNA damage (Bregman et al., 1996; Ratner et
CstF-50 and BARD1/BRCA1. We found that extracts al., 1998). This modification can be detected within 15
from cells treated with UV or HU were strongly, but min after exposing HeLa cells to UV irradiation, persists
transiently, inhibited for 39 pre-mRNA cleavage, and that for about 8–12 hr (Bregman et al., 1996), and appears
both BARD1 and CstF were implicated in the inhibition. to require CTD phosphorylation, characteristic of elon-
Furthermore, cells with decreased polyadenylation ac- gating RNAP II (Ratner et al., 1998; Mitsui and Sharp,
tivity displayed a corresponding increase in the levels 1999). Importantly, ubiquitination is accompanied by
of a CstF/BARD1/BRCA1 complex. Together, our results transient reductions of RNAP II levels, likely mediated
indicate that the interaction between BARD1/BRCA1 by proteasomal degradation (Ratner et al., 1998). These
and CstF mediates a transient inhibition of polyadenyla- results suggest that during TCR, the elongating RNAP
tion in response to DNA damage, and provide evidence II complexes that arrest at intragenic DNA lesions abort
for an unexpected link between 39 pre-mRNA pro- rather than resume elongation after repair takes place.
cessing and DNA repair. The importance of this interac- What might be the relationship among these disparate
tion for normal cell growth is illustrated by the inactivity events, BRCA1/BARD1 changes, transcription, 39 end
of the Gln564His tumor-associated BARD1 mutant. processing, DNA replication and repair, ubiquitination,
The levels of 39 end processing and CstF/BARD1/ and degradation of RNAP II, all of which are affected in
BRCA1 complex formation in HeLa cells treated with response to DNA damage? We propose a model that
DNA damaging agents were not affected until at least extends the concept of TCR. TCR depends on the pas-
1 hr after treatment. Several cellular events, likely related sage of RNAP II across sites of DNA damage, and DNA
to these observations, occur in a similar time frame lesions that interfere with transcription elongation may
after DNA damage. For example, Scully et al. (1997b) be substrates for TCR (reviewed by de Laat et al., 1999).
described changes in the phosphorylation state of The DNA lesions themselves could cause premature
BRCA1 and the subnuclear localization of BARD1 and transcription termination or arrest, or arrest could occur
BRCA1 in S phase following treatment with HU or UV, via interaction of one of the factors of the RNAP II holo-
enzyme with an element of the replication/repair ma-resulting in the recruitment of BRCA1/BARD1 to PCNA/
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chinery, such as PCNA. In any event, the BARD1/ a response that could again reflect reduced activity of
the general polyadenylation machinery. For example,BRCA1-containing complex is recruited to such sites to
participate in TCR. These events, we suggest, act as our previous studies showed that increasing or decreas-
ing the intracellular levels of CstF-64 affects alternativea premature termination signal causing release of the
stalled RNAP II, thereby exposing nascent transcripts poly(A) site selection in synthesis of membrane versus
secreted forms of IgM in DT40 cells (Takagaki et al.,to possible erroneous polyadenylation. Inhibition of the
polyadenylation machinery prevents inappropriate, and 1996; Takagaki and Manley, 1998). BARD1-mediated
inhibition of CstF activity could have similar gene-spe-potentially deleterious, RNA processing. Inhibition oc-
curs through the interaction of CstF with BARD1/ cific effects.
Our data provide evidence for a link between pre-BRCA1, both of which have been shown to associate
with the RNAP II holoenzyme (McCracken et al., 1997; mRNA processing and tumor suppression. The pres-
ence of the Gln564His germline mutation studied hereScully et al., 1997a). Given that the CTD itself is neces-
sary for efficient 39 cleavage in vitro (Hirose and Manley, was accompanied by loss of the wild-type BARD1 allele
in malignant but not normal tissues, indicating that the1998), degradation of RNAP II following ubiquitination
could, therefore, also contribute to the inhibition of 39 only BARD1 protein expressed in the tumor cells was
the mutated version (Thai et al., 1998). According to ourprocessing. Both BRCA1 and BARD1 contain RING fin-
gers, and one or both could participate directly in ubiqui- results, it is highly probable that the malignant cells
display altered levels of polyadenylation of certaintination of RNAP II (Lorick et al., 1999). Intriguingly, and
consistent with our data, a link between DNA repair and mRNAs. Several lines of evidence indicate that the levels
of polyadenylation must be tightly regulated: enhancedpolyadenylation has also emerged from recent studies
by de Vries et al. (2000). These authors purified the 39 polyadenylation has been detected in certain tumor cells
(breast cancer, Scorilas et al., 1998; B cell lymphomas,cleavage factor CFIIm, and found that it copurifies with
several other polypeptides, including TFIIH subunits p52 Kumar et al., 1995), and PAP is known to be inactivated
in M phase (Colgan et al., 1996; 1998). Cells expressingand p89, and, significantly, the BRCA1-associated pro-
tein hMre11, which has been implicated in DNA repair a mutant PAP that cannot be downregulated display
reduced growth rates, and even very modest overex-and cancer predisposition (reviewed by Petrini, 2000).
Our data revealed a dramatic inhibition of 39 end for- pression of wild-type PAP can interfere with cell growth
(Zhao and Manley, 1998). Taken together, it can be con-mation in nuclear extracts from cells treated with DNA
damage-inducing agents that persists for a period of cluded that repression of polyadenylation is an impor-
tant event in controlling cell growth, and that BARD1several hours. A significant question is whether this re-
flects a global inhibition of 39 processing, or a more can play an important role in this process. It is possible
that the BARD1 Gln564His mutation interferes with neg-selective inhibition, for example associated directly with
TCR. We believe the answer is most likely the latter. A ative control of polyadenylation, resulting in enhanced
or inappropriate expression of specific genes.prolonged inhibition of mRNA 39 end formation would
be expected to have a more deleterious effect on cell BARD1 is ubiquitously expressed (Ayi et al., 1998) and
our previous results (Kleiman and Manley, 1999) suggestgrowth than the modest reduction in cycling cells that
we observed. In addition, sizeable decreases in mRNA that its inhibitory effect on polyadenylation is likely to be
general. How might alterations in a general pre-mRNAproduction following UV-induced DNA damage have not
been documented (e.g., Ljungman, 1999; Rockx et al., processing factor cause tissue-specific disease? The
effects of altered CstF-64 levels in B cells provides an2000), and our own experiments employing pulse label-
ing with 3H uridine revealed only a relatively small de- example of how a general factor can have gene-specific
effects. Decreased intracellular concentrations of CstF-crease in poly(A)1 versus total RNA synthesis (unpub-
lished data). It is likely that the substantial reduction in 64 were shown to specifically reduce not only alternative
processing, but also accumulation of IgM heavy chain39 processing observed in vitro reflects the nature of
the nuclear extracts. For example, the concentration of mRNA, as well as cause cell cycle arrest, while increased
CstF-64 levels reverse the cell cycle arrest and activateCstF appeared to be limiting for efficient cleavage in
these extracts, and it may be that reduction in CstF heavy chain mRNA expression (Takagaki and Manley,
1998). These changes in CstF-64 levels affect expres-activity (by interaction with BARD1/BRCA1) has a quan-
titatively more significant effect in vitro than in vivo. sion of very few genes (Takagaki and Manley, 1998; Y.
Takagaki and J. L. M., unpublished data), indicating thatConsistent with this, our previous studies showed that
reduction in the intracellular concentration of CstF-64 only a small subset of B cell mRNAs are sensitive to
changes in CstF. These results support the idea thatby a factor of 5–10 in the chicken B cell line DT40 did
not significantly affect cell growth or accumulation of the general 39 processing machinery could have tissue-
specific effects not because of the presence of tissue-most mRNAs (Takagaki and Manley, 1998).
Another interesting link between DNA repair and poly- specific factors in the complexes, but due to character-
istics of the target transcripts.adenylation is provided by a study documenting en-
hanced synthesis of the protein elastin in sun-damaged Based on properties of BRCA1, BARD1, and CstF, we
propose that BARD1, as part of a complex recruited toskin (Schwartz et al., 1998). Both sun-damaged human
skin and UV-irradiated fibroblasts display elevated lev- the elongating RNAP II holoenzyme, senses sites of DNA
damage, or other sites that cause RNAP II stalling, andels of elastin synthesis, and this increase was shown to
correlate with the expression of a tropoelastin mRNA that the inhibitory interaction with CstF ensures that
nascent RNAs are not erroneously polyadenylated. Thevariant produced by alternative polyadenylation. These
results suggest that selection of alternative polyadenyla- absence of functional BARD1 would allow expression
of aberrant versions of specific transcripts, includingtion sites could be altered in response to DNA damage,
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39 Cleavage Assaysperhaps some regulated in a tissue-specific manner,
32P-labeled SV40 late and L3 pre-mRNA substrates were preparedwhich could in turn trigger the transformation process.
as described (Kleiman and Manley, 1999). Protein concentrationsWhile further experiments are necessary to test the de-
of the extracts were equalized by Bradford assays (BioRad) and/or
tails of this mechanism, our data not only indicate the by Coomassie blue staining before use in processing reactions.
existence of an unexpected link between RNA pro- Cleavage assays with equivalent amounts of total protein were car-
ried out in reaction mixtures containing 0.2–0.5 ng labeled RNA, 250cessing and DNA repair, but also suggest that loss of
ng tRNA, 0.25 U RNasin (Promega), 8 mM Tris pH 7.9, 10% glycerol,wild-type BARD1 protein could lead to defective control
20 mM creatine phosphate, 120 mM NaCl, 0.2 mM DTT, 2.5% polyvi-of gene expression as a result of inappropriate polyade-
nyl alcohol, and 0.2 mM PMSF. NE and added proteins or antibodiesnylation.
were preincubated for 15 min at 308C, after which the pre-mRNA
was added and incubation continued for an additional 90 min. RNA
Experimental Procedures
products were isolated and fractionated on 5% polyacrylamide, 8.3
M urea gels. CstF was purified from HeLa cells through the MonoS
Tissue Culture Methods and DNA Damaging Agents
step (Takagaki et al., 1990), and added to processing reactions as
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium
indicated.
(DMEM)-10% fetal bovine serum (FBS). 80% confluent cultures were
exposed to DNA damaging agents and then harvested at the stated
Cell Cycle Analysistimes. HU (Calbiochem) was added to a final concentration of 1
Similar density cultures of HeLa cells were irradiated, and 1 3 106mM. UV doses (10 Jm22) were delivered in a single pulse using a
cells were used for fluorescence-activated cell sorter (FACS) analy-Stratalinker (Stratagene). Prior to pulsing, medium was removed,
sis. Cellular DNA was stained with propidium iodide (Sigma) asand replaced immediately after treatment.
described (Chen and Manley, 2000). DNA content was measured
by a FACS Calibur (Becton Dickinson) and cell cycle profiles were
Nuclear Extracts Preparation and Immunoblotting Analysis
analyzed by the ModFit program (Verity Software).
After drug treatment, NEs were prepared from harvested cells (<3 3
107) essentially as described (Lee et al., 1988). Cells were lysed by
In Vitro Splicingdouncing in 4 ml of 10 mM Tris pH 7.9, 1.5 mM MgCl2, 10 mM 32P-labeled pre-mRNA substrates were prepared as describedKCl, 0.5 mM dithiothreitol (DTT), and 0.5 mM phenylmethylsulfonyl
(Tacke et al., 1998). Splicing reactions were carried out at 308C forfluoride (PMSF). Lysates were centrifuged for 10 min at 6000 g, and
80 min in 15 ml containing 15 mg of each NE. The final concentrationspellets were resuspended in 20 mM Tris pH 7.9, 1.5 mM MgCl2, 25%
of buffer components were 1–2 ng labeled RNA, 0.16 U RNasinglycerol, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and 0.3 M
(Promega), 8 mM Tris pH 7.9, 10% glycerol, 120 mM NaCl, 10 mMNaCl. Preparations were rocked for 30 min at 48C and centrifuged
creatine phosphate, 0.2 mM DTT, 2% polyvinyl alcohol, 0.2 mMfor 15 min at 6000 g. Supernatants were quick frozen and stored at
PMSF, 1 mM ATP, 0.13 mM EDTA, and 2.6 mM MgCl2. Splicing2808C. Sixty mg of each NE was analyzed by immunoblotting with
products were deproteinized and analyzed on 6% polyacrylamide,mAbs targeted against BARD1 (EE6; Wu et al., 1996), CstF-64 (Taka-
8 M urea gels.gaki et al., 1990), CPSF-160 (Murthy and Manley, 1995), or BRCA1
(MS110; Scully et al., 1996). SDS-PAGE conditions to allow detection
Acknowledgmentsof changes in BRCA1 mobility were as described previously (Scully
et al., 1997b).
We thank C. Shin for help with the splicing reactions, Y. Takagaki for
CstF plasmids, A. M. Bowcock for Gln564His and wild-type BARD1Immunoprecipitation Analysis
cDNAs, R. Baer for BARD1- and BRCA1-encoding plasmids andOne hundred mg total protein from each NE was immunoprecipitated
anti-BARD1 antibodies, Y. Hirose for HeLa nuclear extract, J. Chenwith the anti-CstF-64 or BRCA1 mAbs bound to protein A-Sepharose
and D. Livingston for the anti-BRCA1 antibodies, K. Murthy for thebeads as indicated. Immunoprecipitations were carried out for 90
anti-CPSF-160 antibodies, and C. Prives, R. Baer, and A. Bowcockmin at 48C in 20 ml of buffer A (13 phosphate-buffered saline (PBS):
for advice and discussions. This work is supported by NIH grant137 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 0.01%
GM28983 to J.L.M., Avon Products Foundation Breast Cancer Re-Nonidet P-40, and 0.04% bovine serum albumin). Washing was with
search and Care Program, and an NIH Fogarty Fellowship to F. E. K.buffer B (buffer A plus 100 mM NaCl). Aliquots of pellets and super-
natants were analyzed by SDS-PAGE and immunoblotting.
Received July 17, 2000; revised January 16, 2001.
GST Fusion Proteins
ReferencesThe Gln564His and a corresponding wild-type cDNAs were isolated
from a tumor of a woman with a clear cell adenocarcinoma of the
Anderson, S.F., Schlegel, B.P., Nakajima, T., Wolpin, E.S., and Par-ovary (Thai et al., 1998). The GST-BARD1 and GST-Gln564His deriv-
vin, J.D. (1998). BRCA1 protein is linked to the RNA polymerase IIatives were obtained by inserting a 114 bp NheI-AflII restriction
holoenzyme complex via RNA helicase A. Nat. Genet. 19, 254–256.fragment, which encompasses the mutation, into the previously de-
scribed GST-BARD1 (Kleiman and Manley, 1999). The presence of Ayi, T.C., Tsan, J.T., Hwang, L.Y., Bowcock, A.M., and Baer, R.
the mutation was verified by DNA sequencing. cDNAs encoding (1998). Conservation of function and primary structure in the BRCA1-
BARD1 derivates were expressed in E. coli., and purified by binding associated RING domain (BARD1) protein. Oncogene 17, 2143–
to and elution from glutathione-agarose beads as described (Klei- 2148.
man and Manley, 1999). Bhattacharyya, A., Ear, U.S., Koller, B.H., Weichselbaum, R.R., and
Bishop, D.K. (2000). The breast cancer-susceptibility gene BRCA1
Protein–Protein Interaction Assays is required for subnuclear assembly of Rad51 and survival following
CstF-50, BARD1, and BRCA1 were generated by in vitro translation treatment with the DNA crosslinking agent cisplatin. J. Biol. Chem.
in rabbit reticulocyte lysate (TNT, Promega). Six ml of the 35S-labeled 275, 23899–23903.
CstF-50, BARD1, or BRCA1 lysate was incubated with 1 mg of the
Bregman, D.B., Halaban, R., van Gool, A.J., Henning, K.A., Friedberg,
indicated GST fusion protein for 30 min at 308C in 20 ml final volume
E.C., and Warren, S.L. (1996). UV-induced ubiquitination of RNA
buffer A. Binding mixtures were then incubated with glutathione-
polymerase II: a novel modification deficient in Cockayne syndrome
agarose beads for 90 min at 48C, and the beads were washed four
cells. Proc. Natl. Acad. Sci. USA 93, 11586–11590.
times with buffer C (buffer A plus 300 mM NaCl) or other washing
Chapman, M.S., and Verma, I.M. (1996). Transcriptional activationconditions as indicated, resuspended in loading buffer, and proteins
by BRCA1. Nature 382, 678–679.fractionated by 8% SDS-PAGE. Alternatively, 10 ml of HeLa cell NEs
were incubated with 1 mg of the indicated GST fusion proteins; the Chen, Z., and Manley, J.L. (2000). Robust mRNA transcription in
chicken DT40 cells depleted of TAFII31 suggests both functionalbinding and washing conditions were as before.
Cell
752
degeneracy and evolutionary divergence. Mol. Cell. Biol. 20, 5064– II large subunit signaled by phosphorylation of carboxyl-terminal
domain. Proc. Natl. Acad. Sci. USA 96, 6054–6059.5076.
Chuvpilo, S., Zimmer, M., Kerstan, A., Glockner, J., Avots, A., Escher, Moynahan, M.E., Chiu, J.W., Koller, B.H., and Jasin, M. (1999). Brca1
controls homology-directed DNA repair. Mol. Cell 4, 511–518.C., Fischer, C., Inashkina, I., Jankevics, E., Berberich-Siebelt, F.,
et al. (1999). Alternative polyadenylation events contribute to the Murthy, K.G.K., and Manley, J.L. (1995). The 160-kD subunit of hu-
induction of NF-Atc in effector T cells. Immunity 10, 261–269. man cleavage-polyadenylation specificity factor coordinates pre-
mRNA 39-end formation. Genes Dev. 9, 2672–2683.Colgan, D.F., and Manley, J.L. (1997). Mechanism and regulation of
mRNA polyadenylation. Genes Dev. 11, 2755–2766. Neer, E.J., Schmidt, C.J., Nambudripad, R., and Smith, T.F. (1994).
The ancient regulatory-protein family of WD-repeat proteins. NatureColgan, D.F., Murthy, K.G.K., Prives, C., and Manley, J.L. (1996). Cell-
cycle related regulation of poly(A) polymerase by phosphorylation. 371, 297–300.
Nature 384, 282–285. Ouchi, T., Monteiro, A.N.A., August, A., Aaronson, S.A., and Hana-
fusa, H. (1998). BRCA1 regulates p53-dependent gene expression.Colgan, D.F., Murthy, K.G.K., Zhao, W., Prives, C., and Manley, J.L.
(1998). Inhibition of poly(A) polymerase requires p34cdc2/cyclin B Proc. Natl. Acad. Sci. USA 95, 2302–2306.
phosphorylation of multiple consensus and non-consensus sites. Petrini, J.H. (2000). The Mre11 complex and ATM: collaborating to
EMBO J. 17, 1053–1062. navigate S phase. Curr. Opin. Cell Biol. 12, 293–296.
Dantonel, J.C., Murthy, K.G.K., Manley, J.L., and Tora, L. (1997). Ratner, J.N., Balasubramanian, B., Corden, J., Warren, S.L., and
Transcription factor TFIID recruits factor CPSF for formation of 39 Bregman, D.B. (1998). Ultraviolet radiation-induced ubiquitination
end of mRNA. Nature 389, 399–402. and proteosomal degradation of the large subunit of RNA polymer-
ase II. Implications for transcription-coupled DNA repair. J. Biol.de Laat, W.L., Jaspers, N.G.J., and Hoeijmakers, J.H.J. (1999). Mo-
lecular mechanism of nucleotide excision repair. Genes Dev. 13, Chem. 273, 5184–5189.
768–785. Rockx, D.A.P., Mason, R., van Hoffen, A., Barton, M.C., Citterio, E.,
Bregman, D.B., van Zeeland, A.A., Vrieling, H., and Mullenders, L.H.de Vries, H., Ru¨egsegger, U., Hu¨bner, W., Friedlein, A., Langen, H.,
and Keller, W. (2000). Human pre-mRNA cleavage factor IIm contains (2000). UV-induced inhibition of transcription involves repression of
transcription initiation and phosphorylation of RNA polymerase II.homologs of yeast proteins and bridges two other cleavage factors.
EMBO J. 19, 5895–5904. Proc. Natl. Acad. Sci. USA 97, 10503–10508.
Ruffner, H., and Verma, I. (1997). BRCA1 is a cell cycle-regulatedGowen, L.C., Avrutskaya, A.V., Latour, A.M., Koller, B.H., and Lea-
don, S.A. (1998). BRCA1 required for transcription-coupled repair nuclear phosphoprotein. Proc. Natl. Acad. Sci. USA 94, 7138–7143.
of oxidative DNA damage. Science 281, 1009–1012. Schwartz, E., Gelfand, J.M., Mauch, J.C., and Kligman, L.H. (1998).
Generation of a tropoelastin mRNA variant by alternative polyade-Hirose, Y., and Manley, J.L. (1998). RNA polymerase II is an essential
mRNA polyadenylation factor. Nature 395, 93–96. nylation site selection in sun-damaged human skin and ultraviolet
B-irradiated fibroblasts. Biochem. Biophys. Res. Commun. 246,Hirose, Y., and Manley, J.L. (2000). RNA polymerase II and the inte-
217–221.gration of nuclear events. Genes Dev. 14, 1415–1429.
Scorilas, A., Courtis, N., Yotis, J., Talieri, M., Michailakis, M., andIrminger-Finger, I., Soriano, J.V., Vaudan, G., Montesano, R., and
Trangas, T. (1998). Poly(A) polymerase activity levels in breast tu-Sappino, A.P. (1998). In vitro repression of BRCA1-associated RING
mour cytosols. J. Exp. Clin. Cancer Res. 17, 511–518.domain gene, BARD1, induces phenotypic changes in mammary
epithelial cells. J. Cell. Biol. 143, 1329–1339. Scully, R., Ganesan, S., Brown, M., De Caprio, J.A., Cannistra, S.A.,
Feunteun, J., Schnitt, S., and Livingston, D.M. (1996). Location ofJin, Y., Xu, X.L., Yang, M.C.W., Wei, F., Ayi, T.C., Bowcock, A.M.,
BRCA1 in human breast and ovarian cell lines. Science 272, 123–125.and Baer, R. (1997). Cell cycle-dependent colocalization of BARD1
and BRCA1 proteins in discrete nuclear domains. Proc. Natl. Acad. Scully, R., Anderson, S.F., Chao, D.M., Wei, W., Ye, L., Young, R.A.,
Livingston, D.M., and Parvin, J.D. (1997a). BRCA1 is a componentSci. USA 94, 12075–12080.
of the RNA polymerase II holoenzyme. Proc. Natl. Acad. Sci. USAKleiman, F.E., and Manley, J.L. (1999). Functional interaction of
94, 5605–5610.BRCA1-associated BARD1 with polyadenylation factor CstF-50.
Science 285, 1576–1579. Scully, R., Chen, J., Ochs, R.L., Keegan, K., Hoekstra, M., Feunteun,
J., and Livingston, D.M. (1997b). Dynamic changes of BRCA1 sub-Kumar, A., Kurl, R.N., Kryworuchko, M., Diaz-Mitoma, F., and
nuclear location and phosphorylation state are initiated by DNASharma, S. (1995). Differential effect of heat shock on RNA metabo-
damage. Cell 90, 425–435.lism in human Burkitt’s lymphoma B-cell lines. Leuk. Res. 19,
831–840. Tacke, R., Tohyama, M., Ogawa, S., and Manley, J.L. (1998). Human
Tra2 proteins are sequence-specific activators of pre-mRNA splic-Lee, K.A., Bindereif, A., and Green, M.R. (1988). A small-scale proce-
ing. Cell 93, 139–148.dure for preparation of nuclear extracts that support efficient tran-
scription and pre-mRNA splicing. Gene Anal. Tech. 5, 22–31. Takagaki, Y., and Manley, J.L. (1992). A human polyadenylation
factor is a G protein b-subunit homolog. J. Biol. Chem. 267, 23471–Ljungman, M. (1999). Recovery of RNA synthesis from the DHFR
23474.gene following UV-irradiation precedes the removal of photolesions
from the transcribed strand. Carcinogenesis 20, 395–399. Takagaki, Y., and Manley, J.L. (1994). A polyadenylation factor sub-
unit is the human homolog of the Drosophila suppressor of forkedLorick, K.L., Jensen, J.P., Fang, S., Ong, A.M., Hatakeyama, S., and
protein. Nature 372, 471–474.Weissman, A.M. (1999). RING fingers mediate ubiquitin-conjugating
enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA Takagaki, Y., and Manley, J.L. (1997). RNA recognition by the human
polyadenylation factor CstF. Mol. Cell. Biol. 17, 3907–3914.96, 11364–11369.
MacDonald, C.C., Wilusz, J., and Shenk, T. (1994). The 64-kilodalton Takagaki, Y., and Manley, J.L. (1998). Levels of polyadenylation
factor CstF-64 control IgM heavy chain mRNA accumulation andsubunit of the CstF polyadenylation factor binds to pre-mRNAs
downstream of the cleavage site and influences cleavage site loca- other events associated with B cell differentiation. Mol. Cell 2,
761–771.tion. Mol. Cell. Biol. 14, 6647–6654.
McCracken, S., Fong, N., Yankulov, K., Ballantyne, S., Pan, G., Takagaki, Y., Manley, J.L., MacDonald, C.C., Wilusz, J., and Shenk,
T. (1990). A multisubunit factor, CstF, is required for polyadenylationGreenblatt, J., Patterson, S.D., Wickens, M., and Bentley, D.L. (1997).
The C-terminal domain of RNA polymerase II couples mRNA pro- of mammalian pre-mRNAs. Genes Dev. 4, 2112–2120.
cessing to transcription. Nature 385, 357–361. Takagaki, Y., Seipelt, R.L., Peterson, M.L., and Manley, J.L. (1996).
The polyadenylation factor CstF-64 regulates alternative processingMeza, J.E., Brzovic, P.S., King, M.C., and Klevit, R.E. (1999). Mapping
the functional domains of BRCA1. Interaction of the RING finger of IgM heavy chain pre-mRNA during B cell differentiation. Cell 87,
941–952.domains of BRCA1 and BARD1. J. Biol. Chem. 274, 5659–5665.
Mitsui, A., and Sharp, P.A. (1999). Ubiquitination of RNA polymerase Thai, T.H., Du, F., Tsan, J.T., Jin, Y., Phung, A., Spillman, M.A.,
Pre-mRNA Processing and DNA Repair
753
Massa, H.F., Muller, C.Y., Ashfaq, R., Mathis, J.M., Miller, D.S., et
al. (1998). Mutations in the BRCA1-associated RING domain
(BARD1) gene in primary breast, ovarian and uterine cancers. Hum.
Mol. Genet. 7, 195–202.
Welcsh, P.L., Owens, K.N., and King, M.C. (2000). Insights into the
functions of BRCA1 and BRCA2. Trends Genet. 16, 69–74.
Wu, L.C., Wang, Z.W., Tsan, J.T., Spillman, M.A., Phung, A., Xu,
X.L., Yang, M.C.W., Hwang, L.Y., Bowcock, A.M., and Baer, R. (1996).
Identification of a RING protein that can interact in vivo with the
BRCA1 gene product. Nat. Genet. 14, 430–440.
Yu, X., Wu, L.C., Bowcock, A.M., Aronheim, A., and Baer, R. (1998).
The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP,
a protein implicated in the CtBP pathway of transcriptional repres-
sion. J. Biol. Chem. 273, 25388–25392.
Zhao, W., and Manley, J.L. (1998). Deregulation of poly(A) polymer-
ase interferes with cell growth. Mol. Cell. Biol. 18, 5010–5020.
Zhao, J., Hyman, L., and Moore, C. (1999). Formation of mRNA 39
ends in eukaryotes: mechanism, regulation, and interrelationships
with other steps in mRNA synthesis. Microbiol. Mol. Biol. Rev. 63,
405–445.
